Clinical Trials Sponsored by BioMedicines

Total 195 results

Endeavor Biomedicines, Inc.

Completed

A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

Canada, Malaysia, Australia, Mexico, Korea, Republic of
Endeavor Biomedicines, Inc.

Active, not recruiting

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Solid Tumors With PTCH1 Loss-of-function Mutations

United States
Endeavor Biomedicines, Inc.

Completed

A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

Idiopathic Pulmonary Fibrosis

Australia
Aeonvital Biomedicine

Not yet recruiting

A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors

Advanced Solid Tumor
Miltenyi Biomedicine GmbH

Not yet recruiting

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Non Hodgkin Lymphoma

United States
GAIA BioMedicine Inc.

Recruiting

Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

NSCLC | Cell Therapy

Japan
Miltenyi Biomedicine GmbH

Not yet recruiting

MB-CART19.1 in Refractory SLE

SLE - Systemic Lupus Erythematosus

Germany
Miltenyi Biomedicine GmbH

Active, not recruiting

MB-CART20.1 Lymphoma

Non-Hodgkin's Lymphoma | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

Germany
Miltenyi Biomedicine GmbH

Recruiting

DALY 2.0 USA/ MB-CART2019.1 for DLBCL

DLBCL

United States
Miltenyi Biomedicine GmbH

Recruiting

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory

Germany
Miltenyi Biomedicine GmbH

Completed

A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers

COVID-19

Germany
BioMedicines
National Cancer Institute (NCI)

Completed

Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer

Kidney Cancer | Drug Extravasation

United States
Cellular Biomedicine Group Ltd.

Not yet recruiting

Allogenic Adipose-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis

Knee Osteoarthritis

China
Cellular Biomedicine Group Ltd.

Recruiting

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Miltenyi Biomedicine GmbH
Cromsource

Recruiting

Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis (SAVE)

Preeclampsia

Germany, United Kingdom
Cellular Biomedicine Group Ltd.

Recruiting

A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (ELEVATION)

Relapsed/Refractory Large B-Cell Lymphoma

China
Miltenyi Biomedicine GmbH
ICON plc

Active, not recruiting

Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)

B-cell Non Hodgkin Lymphoma

Germany
Eisai Inc.
H3 Biomedicine Inc.

Withdrawn

A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102

Urinary Bladder Neoplasms

United States
Jiangsu Sinorda Biomedicine Co., Ltd

Completed

Single-dose and Multiple-dose X842 Phase 1 Study

Healthy Volunteers

China
Eisai Inc.
H3 Biomedicine Inc.

Completed

A Study to Evaluate the Food-Effect of H3B-6527

Healthy Participants

United States
Imbioray (Hangzhou) Biomedicine Co., Ltd.

Recruiting

Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors

Solid Tumors

China
Miltenyi Biomedicine GmbH
ICON plc

Recruiting

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU)

Diffuse Large B-cell Lymphoma

Spain, Germany, Netherlands, Belgium, France, Czechia, Austria, Lithuania, Poland, Sweden, Hungary, Italy
H3 Biomedicine Inc.
Eisai Inc.

Completed

Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

Liver Neoplasms | Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | Liver Cancer | Hepatic Cancer | Hepatic Carcinoma

France, United States, Belgium, Spain, Taiwan, Korea, Republic of, Russian Federation, Canada, Italy, Singapore, United Kingdom
Eisai Inc.
H3 Biomedicine Inc.

Terminated

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

Lymphoma | Advanced Solid Tumors

United States, Spain, France, Korea, Republic of, United Kingdom
Asklepios proresearch
Miltenyi Biomedicine GmbH

Terminated

Intra-coronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells (AlsterMACS)

Heart Failure

Germany
Jiangsu Sinorda Biomedicine Co., Ltd

Unknown

Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis

Reflux Esophagitis

China
Fudan University
Cellular Biomedicine Group Ltd.

Recruiting

Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer (TIL)

Cervical Cancer

China
University of Ulm
Miltenyi Biomedicine GmbH

Recruiting

Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (IVITOC)

CIDP

Germany
Vastra Gotaland Region
Miltenyi Biomedicine GmbH

Recruiting

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases (HAITILS)

Metastatic Cutaneous Melanoma | Metastatic Uveal Melanoma

Sweden
Cellular Biomedicine Group Ltd.
RenJi Hospital

Completed

Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis

Osteoarthritis

China
Ruijin Hospital
Cellular Biomedicine Group Ltd.

Recruiting

A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection

Drug-resistant

China
Ruijin Hospital
Cellular Biomedicine Group Ltd.

Unknown

the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease

Alzheimer Disease

China
Cellular Biomedicine Group Ltd.
RenJi Hospital

Completed

Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis

Knee Osteoarthritis

China
GWT-TUD GmbH
Miltenyi Biomedicine GmbH

Terminated

Immunoadsorption in Patients With Severe Systemic Sclerosis

Systemic Scleroderma

Germany
German Heart Institute
Miltenyi Biomedicine GmbH

Completed

Bypass Surgery and CD133 Marrow Cell Injection for Treatment of Ischemic Heart Failure (Cardio133)

Congestive Heart Failure | Previous Myocardial Infarction | Coronary Artery Disease With Need for Bypass Surgery | Myocardial Ischemia, Angina Pectoris

Germany
Ruijin Hospital
Cellular Biomedicine Group Ltd.

Unknown

A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS

Acute Respiratory Distress Syndrome

China
Ruijin Hospital
Cellular Biomedicine Group Ltd.

Completed

A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers

Healthy

China
Cellular Biomedicine Group Ltd.
Fudan University

Unknown

Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer

China
Rambam Health Care Campus
Miltenyi Biomedicine GmbH

Unknown

Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion

Philadelphia Chromosome-positive Chronic Myelocytic Leukemia

Israel
University of Wisconsin, Madison
Miltenyi Biomedicine GmbH

Terminated

Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors

Leukemia | Solid Tumors

United States
Shanghai Children's Medical Center
Miltenyi Biomedicine GmbH

Unknown

MB-CART19.1 in Patients With R/R ALL

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory
Miltenyi Biomedicine GmbH
DLR German Aerospace Center

Recruiting

MB-CART20.1 Melanoma

Melanoma (Skin)

Germany
Medical College of Wisconsin
Miltenyi Biomedicine GmbH

Active, not recruiting

CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Non Hodgkin Lymphoma

United States
Cellular Biomedicine Group Ltd.
Shanghai Zhongshan Hospital

Unknown

AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
EMO Biomedicine Corporation
Far Eastern Memorial Hospital

Completed

Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)

Osteoarthritis,Knee

Taiwan
Dana-Farber Cancer Institute
Miltenyi Biomedicine GmbH

Completed

Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies

Hematologic Malignancies

United States
EMO Biomedicine Corporation
Far Eastern Memorial Hospital

Completed

Large-scale ex Vivo Expansion and Characterization of Two Kinds of MSC From Knee for Clinical Application

Knee Injuries

Taiwan
Wuxi People's Hospital
Imbioray (Hangzhou) Biomedicine Co., Ltd.

Recruiting

Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai East Hospital
Imbioray (Hangzhou) Biomedicine Co., Ltd.

Recruiting

Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Cellular Biomedicine Group Ltd.
Chinese PLA General Hospital

Unknown

A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL

Relapsed or Refractory Acute Lymphoblastic Leukemia

China

Clinical Trials Sponsored by BioMedicines

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations